Astria Therapeutics, Inc.
Astria Therapeutics, Inc.（ATXS）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · ATXS · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
1
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Astria Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
ATXS 季度内部人买卖趋势
ATXS 内幕交易卖出 · ATXS 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · ATXS CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
ATXS 高管卖出股份 · ATXS 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jan 23, 2026 | Violin Jonathan Director | Other | 263,321 | — | Form 4 |
| Jan 23, 2026 | Milne Jill C. CEO and President · Director | Other | 4,377 | — | Form 4 |
| Jan 23, 2026 | Komjathy Andrew Chief Commercial Officer | Other | 45 | — | Form 4 |
| Apr 1, 2024 | Morabito Christopher Chief Medical Officer | Option | 10,000 | $39K | Form 4 |
| Apr 1, 2024 | Morabito Christopher Chief Medical Officer | Sale | 10,000 | $136K | Form 4 |
| Feb 1, 2024 | PERCEPTIVE ADVISORS LLC Director | Purchase | 2,481,350 | $30.00M⚡ | Form 4 |
| Jan 29, 2024 | Morabito Christopher Chief Medical Officer | Option | 9,200 | $36K | Form 4 |
| Jan 26, 2024 | Morabito Christopher Chief Medical Officer | Option | 800 | $3K | Form 4 |
| Jan 29, 2024 | Morabito Christopher Chief Medical Officer | Sale | 9,200 | $103K | Form 4 |
| Jan 26, 2024 | Morabito Christopher Chief Medical Officer | Sale | 800 | $9K | Form 4 |
| Dec 21, 2023 | PERCEPTIVE ADVISORS LLC Director | Purchase | 740,000 | $4.59M⚡ | Form 4 |
| Oct 16, 2023 | PERCEPTIVE ADVISORS LLC Director | Purchase | 614,062 | $4.00M⚡ | Form 4 |
| Oct 16, 2023 | PERCEPTIVE ADVISORS LLC Director | Purchase | 460,546 | $3.00M⚡ | Form 4 |
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 ATXS 内幕交易
ATXS 内幕交易
Astria Therapeutics, Inc.（ATXS）内幕交易数据来源于公司内部人（包括Violin Jonathan (Director), Milne Jill C. (CEO and President · Director), Komjathy Andrew (Chief Commercial Officer)）提交的SEC Form 4申报文件。过去12个月内，3位内部人向SEC提交了交易申报。ATXS内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Astria Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
ATXS 内幕交易 · 5个问题Astria Therapeutics, Inc.（ATXS）的内部人包括高管和董事，如Violin Jonathan (Director), Milne Jill C. (CEO and President · Director), Komjathy Andrew (Chief Commercial Officer)等。过去12个月内，3位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026